RGS17: A Non-Coding RNA Molecule with Potential as A Drug Target and Biomarker for Cancer

Target Name: RGS17

NCBI ID: G26575

RGS17

RGS17: A Non-Coding RNA Molecule with Potential as A Drug Target and Biomarker for Cancer

RGS17 (RGSZ2) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and biology make it an attractive target for drug development due to its ability to regulate gene expression and contribute to the development of cancer. In this article, we will discuss the biology and potential drug targets of RGS17, as well as its potential as a biomarker for cancer diagnosis and treatment.

Biology and Function

RGS17 is a non-coding RNA molecule that was identified as a potential drug target by its ability to interact with the protein known as p53, a well-known tumor suppressor protein. p53 plays a crucial role in regulating gene expression and has been implicated in the development and progression of many diseases, including cancer. By interacting with p53, RGS17 has the potential to regulate gene expression and contribute to the development of cancer.

In addition to its potential role in cancer, RGS17 has also been shown to have a positive impact on overall health and well-being. Studies have shown that RGS17 levels are reduced in various tissues and organisms, including cancer cells, and that it has the potential to be a therapeutic target for diseases associated with decreased RGS17 levels, such as cancer.

Potential Drug Targets

RGS17 has been identified as a potential drug target due to its ability to interact with multiple proteins, including p53. This makes it an attractive target for drug development due to its potential to modulate gene expression and contribute to the development of cancer.

One of the main potential drug targets for RGS17 is the p53 protein. Activated p53 has been shown to contribute to the development and progression of many diseases, including cancer. By interacting with p53, RGS17 has the potential to regulate gene expression and potentially inhibit its activity, leading to the inhibition of cancer development.

Another potential drug target for RGS17 is the NF-kappa-B signaling pathway. NF-kappa-B is a protein that plays a role in regulating gene expression and has been implicated in the development and progression of many diseases, including cancer. RGS17 has been shown to interact with the NF-kappa-B protein, which may indicate that it has the potential to regulate gene expression and contribute to the development of cancer.

In addition to its potential drug targets, RGS17 has also been shown to have a positive impact on overall health and well-being. Studies have shown that RGS17 levels are reduced in various tissues and organisms, including cancer cells, and that it has the potential to be a therapeutic target for diseases associated with decreased RGS17 levels, such as cancer.

Biomarker Potential

RGS17 has also been shown to have potential as a biomarker for cancer diagnosis and treatment. Its unique structure and biology make it an attractive target for diagnostic tests and potential therapeutic approaches.

One of the main potential uses of RGS17 as a biomarker is its ability to interact with the p53 protein. This interaction may indicate that RGS17 has the potential to be a diagnostic tool for cancer, as increased levels of RGS17 may indicate the presence of cancer. Additionally, RGS17 has been shown to have a positive impact on overall health and well-being, which may indicate that it has the potential to be a therapeutic approach for cancer treatment.

Conclusion

In conclusion, RGS17 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and biology make it an attractive target for drug development due to its ability to regulate gene expression and contribute to the development of cancer. Additionally, RGS17 has also been shown to have a positive impact on overall health and well-being, which may indicate that it has the potential to be a therapeutic approach for cancer treatment. Further research is needed to fully understand the biology and potential of RGS17 as a drug target and biomarker for cancer.

Protein Name: Regulator Of G Protein Signaling 17

Functions: Regulates G protein-coupled receptor signaling cascades, including signaling via muscarinic acetylcholine receptor CHRM2 and dopamine receptor DRD2. Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form (PubMed:15096504). Binds selectively to GNAZ and GNAI2 subunits, accelerates their GTPase activity and regulates their signaling activities. Negatively regulates mu-opioid receptor-mediated activation of the G-proteins (By similarity)

The "RGS17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RGS17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets